한글목차

세계의 핵의학 치료제 시장 규모는 2024년에 9억 8,580만 달러로 평가되며, 2030년까지 CAGR은 9.60%로, 예측 기간 중 인상적인 성장이 전망되고 있습니다. 핵의학 치료제는 방사선 치료 또는 방사성 핵종 치료로도 알려진 핵의학의 한 분야로, 방사성 물질(방사성 의약품)을 사용하여 다양한 질병, 특히 암을 치료하는 분야입니다. 환자의 몸 밖에서 발생하는 고에너지 X선이나 기타 방사선을 사용하는 기존의 외부 조사 요법과는 달리, 핵의학 치료제은 체내에 투여되어 체내의 특정 질병 부위를 표적으로 하는 방사성 의약품을 사용합니다. 핵의학 치료를 받는 환자는 치료 중과 치료 후 치료 효과를 평가하고 잠재적인 부작용을 관리하기 위해 주의 깊게 모니터링합니다. 치료 과정과 환자의 상태를 추적하기 위해 추적 영상 진단 및 검사를 시행할 수도 있습니다. 핵의학 치료제는 질병의 유형과 병기, 환자의 전신 건강 상태, 치료에 대한 반응 등의 요소에 따라 환자 개개인에 맞게 조정할 수 있습니다. 이러한 개별화 접근법은 부작용을 최소화하면서 치료 효과를 극대화하는 것을 목표로 합니다.

세계에서 암의 유병률은 지속적으로 증가하고 있으며, 효과적인 진단 및 치료 툴에 대한 수요가 증가하고 있습니다. 핵의학은 암의 진단과 치료 모두에서 중요한 역할을 하고 있으며, PET-CT, SPECT-CT와 같은 영상 기술의 발전으로 진단과 치료 계획의 정확도가 향상되고 있습니다. 보다 효율적이고 컴팩트한 영상 진단 장비의 개발로 핵의학에 대한 접근성이 향상되었습니다. 현재 진행 중인 임상시험과 조사 연구가 핵 의학의 적용 확대에 기여하고 있습니다. 임상시험의 긍정적인 결과는 일상적인 임상에서 핵의학 치료의 채택으로 이어집니다. 세계 인구의 고령화로 인해 암, 심혈관 질환과 같은 만성질환에 걸리기 쉬워지고 있으며, 이러한 질환은 핵의학 기술을 사용하여 진단 및 치료하는 경우가 많으며, 2023년 11월 국립보건연구원(NIHR)의 데이터에 따르면 방사성 의약품은 개발 단계(1/2, 2, 3, 4단계)에 있습니다. 2/3,3단계)에 따라 분류되어 있습니다. 대부분(401건, 62%)은 2상, 약 4분의 1(146건, -23%)은 3상 임상시험 중이었습니다.

주요 시장 성장 촉진요인

기술 발전

주요 시장 이슈

공급망과 방사성동위원소 가용성

주요 시장 동향

방사성 의약품 생산

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 핵의학 치료제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 유형별(알파선원, 베타 선원, 근접 방사선 요법)
  • 용도별(종양학, 심장병학, 갑상선학, 기타 용도)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 핵의학 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 핵의학 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 핵의학 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제9장 남미의 핵의학 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 핵의학 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 핵의학 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals Inc.
• IBA Radiopharma Solutions
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• NTP Radioisotopes Pty Ltd.
• Bracco SpA
• Cardinal Health Inc.
• Nordion Inc.(Sotera Health Company)
• Triad Isotopes Inc.(Jubilant Life Sciences)

제17장 전략적 제안

제18장 조사회사 소개·면책사항

영문목차

Global Nuclear Medicine Therapeutics Market was valued at USD 985.80 million in 2024 and is anticipated to switness an impressive growth in the forecast period with a CAGR of 9.60% through 2030. Nuclear medicine therapeutics, also known as radiotherapy or radionuclide therapy, is a branch of nuclear medicine that involves the use of radioactive materials (radiopharmaceuticals) to treat various medical conditions, particularly cancer. Unlike conventional external beam radiation therapy, which uses high-energy X-rays or other forms of radiation generated outside the patient's body, nuclear medicine therapeutics uses radiopharmaceuticals that are administered internally and target specific disease sites within the body. Patients receiving nuclear medicine therapies are carefully monitored during and after treatment to assess treatment response and manage potential side effects. Follow-up imaging and tests may be performed to track the progress of the therapy and the patient's condition. Nuclear medicine therapeutics can be tailored to individual patients based on factors such as the type and stage of disease, the patient's overall health, and the response to treatment. This personalized approach aims to maximize treatment efficacy while minimizing side effects.

The global prevalence of cancer continues to increase, driving the demand for effective diagnostic and therapeutic tools. Nuclear medicine plays a crucial role in both cancer diagnosis and treatment, making it a critical component of cancer care. Advances in imaging technologies, such as PET-CT and SPECT-CT, have improved the accuracy of diagnosis and treatment planning. The development of more efficient and compact imaging devices has enhanced the accessibility of nuclear medicine. Ongoing clinical trials and research studies have contributed to the expansion of nuclear medicine applications. Positive trial outcomes can lead to the adoption of nuclear medicine therapies in routine clinical practice. The aging global population is more susceptible to chronic diseases, including cancer and cardiovascular conditions, which are often diagnosed and treated using nuclear medicine techniques. According to data from the National Institute for Health Research (NIHR) in November 2023, radiopharmaceuticals have been categorized by their development stage (Phase 1/2, 2, and Phase 2/3, 3). The majority (401, 62%) were in Phase 2, while nearly a quarter (146, ~23%) were in Phase 3 clinical trials.

Key Market Drivers

Advancements in Technology

Technological advancements in nuclear medicine therapeutics have been instrumental in improving the accuracy, effectiveness, and safety of diagnostic and treatment procedures. These advancements have expanded the applications of nuclear medicine and enhanced patient care. Hybrid imaging systems, such as PET-CT (Positron Emission Tomography-Computed Tomography) and SPECT-CT (Single-Photon Emission Computed Tomography-Computed Tomography), have become standard in nuclear medicine. These systems combine functional imaging (PET or SPECT) with anatomical imaging (CT) to provide detailed information about both structure and function in a single scan. This allows for more accurate localization of abnormalities and better treatment planning. PET-MRI combines the functional imaging capabilities of PET with the excellent soft tissue contrast of MRI. This technology is particularly valuable in brain imaging and certain oncology applications, offering improved diagnostic accuracy. Research and development efforts have led to the creation of more targeted and effective radiopharmaceuticals. These radiopharmaceuticals can specifically bind to disease markers or receptors, allowing for more precise diagnosis and targeted therapy. Radioligand therapies involve the use of radiopharmaceuticals that target specific receptors on cancer cells. This approach has shown promise in the treatment of various cancers, such as prostate cancer, using agents like Lutetium-177-PSMA. Advances in alpha-particle-emitting radiopharmaceuticals have gained attention for their high energy and short range, making them effective in targeting cancer cells while sparing surrounding healthy tissue. This approach is being explored for certain types of cancer therapy. Theranostics is an emerging field that combines diagnostic and therapeutic capabilities. It involves the use of radiopharmaceuticals for both imaging and therapy. This approach allows for patient-specific treatment planning based on imaging findings. For instance, In December 2023, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. (POINT) announced topline results from the Phase 3 SPLASH study, evaluating the efficacy and safety of 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibitor (ARPI) treatment. Increasing research investments are expected to drive market growth.

Key Market Challenges

Supply Chain and Radioisotope Availability

Nuclear medicine heavily relies on radioisotopes, which are radioactive materials used in imaging and therapy. The production of these radioisotopes can be complex and is often centralized in a few facilities globally. Any disruptions in production or supply can have widespread implications for nuclear medicine services. Many radioisotopes used in nuclear medicine have short half-lives, meaning they decay rapidly. This necessitates just-in-time production and delivery to healthcare facilities. Any delays in production, transportation, or delivery can lead to radioisotope shortages. The global supply chain for radioisotopes can be vulnerable to various factors, such as technical issues in production facilities, regulatory challenges, geopolitical tensions, and transportation disruptions. These vulnerabilities can lead to interruptions in the supply of radioisotopes. The demand for radioisotopes, especially those used in oncology and cardiology, has been steadily increasing. Meeting this growing demand while ensuring a stable supply chain can be a logistical challenge. There are relatively few facilities worldwide that produce medical-grade radioisotopes. Relying on a small number of production centers increases the risk of supply disruptions. The production of radioisotopes often involves the use of nuclear reactors or particle accelerators, which require specialized infrastructure and expertise. Technical challenges or maintenance shutdowns can affect production. Radioisotopes must be transported under strict safety regulations. Delays or disruptions in transportation can impact the timely delivery of radiopharmaceuticals to healthcare facilities.

Key Market Trends

Radiopharmaceutical Production

The growing awareness of nuclear medicine's diagnostic and therapeutic capabilities has led to an increased demand for radiopharmaceuticals. This trend is driven by the rising prevalence of diseases such as cancer and cardiovascular conditions that benefit from nuclear medicine procedures. Ongoing research and development efforts have led to the creation of a diverse range of radiopharmaceuticals, including those for PET, SPECT, and therapeutic applications. This diversification allows for a broader spectrum of medical conditions to be addressed using nuclear medicine. Radiopharmaceuticals can be designed to target specific disease markers or receptors, enabling more precise diagnosis and therapy. Targeted radiopharmaceuticals are a growing area of interest, particularly in oncology. The concept of theranostics, which combines diagnostic and therapeutic capabilities using the same radiopharmaceutical, has gained traction. Theranostic approaches allow for personalized treatment planning based on diagnostic imaging findings. Improvements in radioisotope production methods have contributed to a more reliable and efficient supply of radiopharmaceuticals. Cyclotron and generator technologies have advanced to support increased production capacity. Efforts have been made to reduce the production time for radiopharmaceuticals with short half-lives. This is crucial for ensuring timely access to these materials.

Key Market Players

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals Inc.
• IBA Radiopharma Solutions
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• NTP Radioisotopes Pty Ltd.
• Bracco SpA
• Cardinal Health Inc.
• Nordion Inc. (Sotera Health Company)
• Triad Isotopes Inc. (Jubilant Life Sciences)

Report Scope:

In this report, the Global Nuclear Medicine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Medicine Therapeutics Market, By Type:

• Alpha Emitters
  • Radium-223 (RA-223) & Alpharadin
  • Actinium-225 (AC-225)
  • Lead-212 (PB-212)/Bismuth-212 (BI-212)
  • Other Alpha Emitters
• Beta Emitters
  • Iodine-131 (I-131)
  • Yttrium-90 (Y-90)
  • Other Beta Emitters
• Brachytherapy
  • Cesium-131
  • Iodine-125
  • Other Brachytherapies

Nuclear Medicine Therapeutics Market, By Application:

• Oncology
• Cardiology
• Thyroid
• Other Applications

Nuclear Medicine Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine Therapeutics Market.

Available Customizations:

Global Nuclear Medicine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Medicine Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Alpha Emitters, Beta Emitters, and Brachytherapy)
  • 5.2.2. By Application (Oncology, Cardiology, Thyroid, and Other Applications)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Nuclear Medicine Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Nuclear Medicine Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. India Nuclear Medicine Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Nuclear Medicine Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Nuclear Medicine Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Nuclear Medicine Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Application

7. Europe Nuclear Medicine Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Nuclear Medicine Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Nuclear Medicine Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Nuclear Medicine Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Nuclear Medicine Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Nuclear Medicine Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. North America Nuclear Medicine Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Nuclear Medicine Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Nuclear Medicine Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Nuclear Medicine Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application

9. South America Nuclear Medicine Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nuclear Medicine Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Nuclear Medicine Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Nuclear Medicine Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Nuclear Medicine Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nuclear Medicine Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Nuclear Medicine Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Nuclear Medicine Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Nuclear Medicine Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Actinium Pharmaceutical Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Alpha Tau Medical Ltd
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Bayer AG
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Fusion Pharmaceuticals Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. IBA Radiopharma Solutions
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. RadioMedix Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Telix Pharmaceuticals Ltd
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. NTP Radioisotopes Pty Ltd.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Bracco SpA
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.Cardinal Health Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis
• 16.11.Nordion Inc. (Sotera Health Company)
  • 16.11.1. Business Overview
  • 16.11.2. Company Snapshot
  • 16.11.3. Products & Services
  • 16.11.4. Financials (In case of listed companies)
  • 16.11.5. Recent Developments
  • 16.11.6. SWOT Analysis
• 16.12.Triad Isotopes Inc. (Jubilant Life Sciences)
  • 16.12.1. Business Overview
  • 16.12.2. Company Snapshot
  • 16.12.3. Products & Services
  • 16.12.4. Financials (In case of listed companies)
  • 16.12.5. Recent Developments
  • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer